Pathophysiology of Chronic Liver Disease Development

Fromme, Malin; Strnad, Pavel

doi:10.3390/ijms23063385

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cirrhosis is notorious for its high mortality rate and dismal prognosis, and its pathogenesis is complicated. Persistent liver damage entails chronic liver diseases (CLDs) and subsequent fibrosis, which will deteriorate into cirrhosis without timely intervention (Fromme & Strnad, 2022; Moon et al, 2020). Thanks to the reversible property of liver fibrosis, developing an effective treatment can interrupt the malignant process of CLDs in the intermediate stage (Tan et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Sclareol attenuates liver fibrosis through SENP1‐mediated VEGFR2 SUMOylation and inhibition of downstream STAT3 signaling

Niu

Bao

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Liver fibrosis is a key global health care burden. Sclareol, isolated from Salvia sclarea, possesses various biological activities. Its effect on liver fibrosis remains unknown. This study was proposed to evaluate the antifibrotic activity of sclareol (SCL) and explore its underlying mechanisms. Stimulated hepatic stellate cells served as an in vitro liver fibrosis model. The expression of fibrotic markers was assessed by western blot and real‐time PCR. Two classical animal models, bile duct‐ligated rats and carbon tetrachloride‐treated mice, were utilized for the in vivo experiments. The liver function and fibrosis degree were determined by serum biochemical and histopathological analyses. VEGFR2 SUMOylation was analyzed using coimmunoprecipitation assay. Our results indicated that SCL treatment restricted the profibrotic propensity of activated HSCs. In fibrotic rodents, SCL administration alleviated hepatic injury and reduced collagen accumulation. Mechanistic studies indicated that SCL downregulated the protein level of SENP1 and enhanced VEGFR2 SUMOylation in LX‐2 cells, which affected its intracellular trafficking. Blockade of the interaction between VEGFR2 and STAT3 was observed, resulting in the suppression of downstream STAT3 phosphorylation. Our findings demonstrated that SCL has therapeutic efficacy against liver fibrosis through mediating VEGFR2 SUMOylation, suggesting that SCL may be a potential candidate compound for its treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Sclareol attenuates liver fibrosis through SENP1‐mediated VEGFR2 SUMOylation and inhibition of downstream STAT3 signaling

Niu

Bao

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…7,9 Autoimmune disease Autoimmune disease represents less than 5% etiology of CLD, include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis 7. …”

mentioning

confidence: 99%

Platelet to White Blood Cell Ratio (PWR) to Predict Mortality in Acute on Chronic Liver Failure of Cirrhosis Patient: A Systematic Review

Pandapotan¹,

Gunawan²

2022

InaJGHE

View full text Add to dashboard Cite

Background: Liver cirrhosis (LC) is still being important public health concern, due to the rising of global incidence and mortality. There is risk progression in LC patients to acute-on-chronic liver failure (ACLF) patients with high incidence of complication and high short-term mortality rate. It needs rapid and simpler predictor to immediate and accurate triage of the patient. The aim of this study is to review systematically the role of PWR to predict the mortality in ACLF cirrhosis patient.Method: This systematic review study was identified by searching Pub-Med, Cochrane library, and EMBASE database (2016-2022). Only observational studies were included. ACLF patient was selected as the main subject in each study, and PWR was added as short-term mortality predictor. The Cochran seven step model was used to perform the review.Results: Six cohort retrospective studies met inclusion criteria, including total 1,348 patient ACLF. Half of studies included had high level of evidence. The non-survivor ACLF patient had significantly lower PWR values than survivor. The range of HR of PWR to predict mortality in ACLF was 0.665-0.995, with p value 0.0001. Whereas the cutoff range of PWR value to predict non survivor in ACLF patient was 7.83-14.2.Conclusion: PWR had a predictive efficacy, similar to CLIF-SOFA and MELD score in terms of predicting short-term mortality in ACLF patients. PWR showed significantly independent risk factor of short term mortality in ACLF cirrhotic patient.

show abstract

Chishao - Fuzi herbal pair restore the macrophage M1/M2 balance in acute-on-chronic liver failure

Tan,

Jian,

Peng

et al. 2024

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Pathophysiology of Chronic Liver Disease Development

Abstract: Chronic liver disease is a major public threat and the second leading cause of loss of working life years in Europe [...]

Cited by 3 publications

References 12 publications

Sclareol attenuates liver fibrosis through SENP1‐mediated VEGFR2 SUMOylation and inhibition of downstream STAT3 signaling

Sclareol attenuates liver fibrosis through SENP1‐mediated VEGFR2 SUMOylation and inhibition of downstream STAT3 signaling

Platelet to White Blood Cell Ratio (PWR) to Predict Mortality in Acute on Chronic Liver Failure of Cirrhosis Patient: A Systematic Review

Chishao - Fuzi herbal pair restore the macrophage M1/M2 balance in acute-on-chronic liver failure

Contact Info

Product

Resources

About